This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Contraindications to the use of infliximab

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The use of anti-TNF agents and the occurrence of severe sepsis and re-activation of tuberculosis has been reported. Their use should be avoided if serious infections (e.g. septic arthritis, acute abcess, systemic fungal infactions) are present or are likely to recur.

The manufacturer of infliximab recommends that patients are screened for tuberculosis prior to therapy, and advised to seek help if they develop symptoms such as persistent cough, weight loss or fever that may suggest tuberculosis. Due to the long half-life of infliximab the patient should be "monitored" closely for infection for at least 6 months after stopping the drug.

Infliximab should be avoided in pregnancy and effective contraceptive measures should be taken. Women should not breast feed for at least 6 months after stopping treatment.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.